Search research articles
Contact Us
Filters
Showing results (91-100 of 100) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 100 results.
Med (New York, N.Y.)
|
August 29, 2025
Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial
Binghao Li, Lu Xie, Junbo Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2025
Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Chunmeng Wang, Xianglin Hu, Lingge Yang, et al.
Experimental & Molecular Medicine
|
March 1, 2019
Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
Zhichao Liao, Feng Li, Chao Zhang, et al.
Oncotarget
|
November 27, 2016
Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
Peipei Xing, Jin Zhang, Zhao Yan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
May 26, 2026
Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma
Zhao Wang, Haotian Liu, Xueqi Wang, et al.
Frontiers in Immunology
|
December 17, 2020
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Xuan Zhou, Sanfang Tu, Chunsheng Wang, et al.
Eclinicalmedicine
|
August 18, 2025
Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study
Zhengfu Fan, Jin Wang, Dan Liu, et al.
Nature Communications
|
November 26, 2022
A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma
Chao Zhang, Hongru Shen, Tielong Yang, et al.
Genome Biology
|
October 31, 2023
Landscape of enhancer disruption and functional screen in melanoma cells
Zhao Wang, Menghan Luo, Qian Liang, et al.
Nature Communications
|
November 5, 2024
Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study
Hairong Xu, Yong Zhou, Li Liang, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 100) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 100 results.
Med (New York, N.Y.)
|
August 29, 2025
Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial
Binghao Li, Lu Xie, Junbo Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2025
Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Chunmeng Wang, Xianglin Hu, Lingge Yang, et al.
Experimental & Molecular Medicine
|
March 1, 2019
Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
Zhichao Liao, Feng Li, Chao Zhang, et al.
Oncotarget
|
November 27, 2016
Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
Peipei Xing, Jin Zhang, Zhao Yan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
May 26, 2026
Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma
Zhao Wang, Haotian Liu, Xueqi Wang, et al.
Frontiers in Immunology
|
December 17, 2020
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Xuan Zhou, Sanfang Tu, Chunsheng Wang, et al.
Eclinicalmedicine
|
August 18, 2025
Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study
Zhengfu Fan, Jin Wang, Dan Liu, et al.
Nature Communications
|
November 26, 2022
A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma
Chao Zhang, Hongru Shen, Tielong Yang, et al.
Genome Biology
|
October 31, 2023
Landscape of enhancer disruption and functional screen in melanoma cells
Zhao Wang, Menghan Luo, Qian Liang, et al.
Nature Communications
|
November 5, 2024
Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study
Hairong Xu, Yong Zhou, Li Liang, et al.
Page
of 10